KLK3 and prostate carcinoma: The use of prostate-specific antigen (PSA) for early detection of prostate cancer (PCa) has been shown to contribute to a favorable shift in tumor-stage at diagnosis resulting in decreased PCa morbidity and mortality [1,2].